The evolution and prognostic impact of HER2‐low, HER2‐ultralow, and HER2‐null status in HER2‐negative early breast cancer: A pre– to post–neoadjuvant chemotherapy study
HER2 expression levels (low/ultralow/null) stratify prognosis in HER2-negative eBC. The dynamic evolution of HER2 status following NAC and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative eBC.
Authors
- Weifeng Cai
- Lili Chen (ORCID: https://orcid.org/0000-0003-0438-8850)
- Fangmeng Fu (ORCID: https://orcid.org/0000-0002-3065-5708)
- C. Wang
- Peng He (ORCID: https://orcid.org/0000-0001-9912-2638)
- Yuxiang Lin
- Shunyi Liu
- Yibin Qiu
- Minyan Chen
- Jie Zhang
- Yinghong Yang
- Long Wu
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Cancer
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1002/cncr.70269
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00